Hi,
It’s been a bit crazy, but I wanted to share that I have posted on our nonprofit’s website http://cllsociety.org an interview from ASH about the particularities of ibrutinib as compared to other BTK inhibitors from the perspective of a Janssen executive, news about a new trialof an experimental BTK inhibitor that doesn’t bind to C481 and is therefore helpful to many who become resistant to ibrutinib due mutations in that binding site, and finally some promising information on CAR-NK cells, a possible steptowards a scalable "off the shelf" cellular therapy.
It seems in CLL, every week brings news and that is a good thing. In contrast and to give some perspective, it has been more than a decade since there has been a new drug to treat MDS
We post new material almost every week. It’s a lot of work, but there is always something new to learn. Please consider signing up for our weekly alert. It helps us. Whether you do or not, as always all our material is free and we never ask you to sign in to see anything on the website. In fact, all our material is available to download.
Stay strong.
We are all in this together.
BrianIf you want a personal response, or just want to stay in touch, please email me at bkoffmanMD@gmail.com. I have no other way of contacting. Thanks. Stay strong. After all, we are all in this together. And please visit our website: http://cllsociety.org for the latest news and information.